Walleye Trading LLC raised its holdings in shares of ViewRay, Inc. (NASDAQ:VRAY – Get Rating) by 58.3% during the 2nd quarter, HoldingsChannel reports. The fund owned 27,379 shares of the company’s stock after purchasing an additional 10,078 shares during the period. Walleye Trading LLC’s holdings in ViewRay were worth $73,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in VRAY. Envestnet Asset Management Inc. lifted its holdings in shares of ViewRay by 4.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 166,631 shares of the company’s stock valued at $653,000 after buying an additional 6,985 shares during the last quarter. ClariVest Asset Management LLC lifted its holdings in shares of ViewRay by 22.3% during the 1st quarter. ClariVest Asset Management LLC now owns 159,600 shares of the company’s stock valued at $626,000 after buying an additional 29,097 shares during the last quarter. Royce & Associates LP acquired a new stake in shares of ViewRay during the 1st quarter valued at about $392,000. Qube Research & Technologies Ltd acquired a new stake in shares of ViewRay during the 1st quarter valued at about $805,000. Finally, Swiss National Bank lifted its holdings in shares of ViewRay by 15.7% during the 1st quarter. Swiss National Bank now owns 313,700 shares of the company’s stock valued at $1,230,000 after buying an additional 42,500 shares during the last quarter. 86.28% of the stock is currently owned by institutional investors and hedge funds.
ViewRay Stock Performance
Shares of NASDAQ:VRAY opened at $4.62 on Monday. The business’s fifty day moving average price is $4.02 and its two-hundred day moving average price is $3.40. ViewRay, Inc. has a fifty-two week low of $2.39 and a fifty-two week high of $5.99. The stock has a market capitalization of $838.14 million, a price-to-earnings ratio of -7.83 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.67 and a quick ratio of 2.30.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on VRAY shares. B. Riley reiterated a “buy” rating on shares of ViewRay in a report on Thursday. BTIG Research reduced their target price on ViewRay to $7.00 in a report on Thursday, October 20th. StockNews.com began coverage on ViewRay in a report on Wednesday, October 12th. They set a “sell” rating for the company. Piper Sandler upped their price target on ViewRay from $6.00 to $6.50 and gave the stock an “overweight” rating in a report on Wednesday, November 2nd. Finally, Morgan Stanley boosted their price objective on ViewRay from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $6.60.
ViewRay, Inc designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns.
- Get a free copy of the StockNews.com research report on ViewRay (VRAY)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for ViewRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay and related companies with MarketBeat.com's FREE daily email newsletter.